Trebananib (AMG-386)
Jump to navigation
Jump to search
In clinical trials
General information
Class/mechanism: Selective angiopoietin 1/2-neutralizing peptibody, interferes with interactions of angiopoietins and Tie2 receptors, inhibiting angiogenesis.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.